Therapies for autoimmune neuropsychiatric diseases

Arialys Therapeutics is focused on developing innovative precision medicines to address autoimmune neuropsychiatric diseases, particularly those driven by pathogenic autoantibodies. The company has identified that immune cells in both the body and the brain can produce autoantibodies that contribute to severe neurological and psychiatric disorders. Their lead therapeutic candidate, ART5803, is a monoclonal antibody designed to specifically block these harmful autoantibodies targeting the NMDA receptor (NMDAR), which is implicated in conditions such as anti-NMDA receptor encephalitis (ANRE). Preclinical studies have shown that ART5803 can effectively reverse the behavioral symptoms associated with NMDAR autoantibody pathogenicity, indicating its potential as a treatment for this rare and often misdiagnosed disease.

In addition to targeting ANRE, Arialys is exploring the broader implications of anti-NMDAR autoantibodies in other neuropsychiatric disorders, including schizophrenia and dementia. The company employs advanced techniques such as co-crystallographic structural analysis to inform their precision medicine approach, ensuring that their therapies are tailored to effectively counteract the specific autoantibody interactions that disrupt normal brain function. With ongoing clinical trials and a commitment to expanding treatment options for patients suffering from these debilitating conditions, Arialys Therapeutics is positioned at the forefront of autoimmune neuropsychiatry research.

United States

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

Arialys Therapeutics

Company Details